Key Takeaways
- Revenue down, margins up: Full-year revenue fell 7% YoY to ₹393.5 crore on price reductions, but EBITDA rose 13% with margins expanding to 17.3% from 14.3%, helped by lower raw material costs.
- SDA volume poised to surge 50%: All customer qualifications are complete and EUR 7 regulation will drive structural demand, but price reductions mean revenue will grow only 25% maximum in FY25.
- PASC validation progressing, commercialization begins: Two products have started commercial production; all five pharma and agro products have received informal positive feedback, with formal validation expected in due time.
- New plant delayed by soil testing failure: The planned seven-floor multi-story plant at Dahej cannot proceed at the tested site; three alternatives are being evaluated, and if none work, the plant will be downsized to four floors, pushing out ₹70 crore of capex by a couple of quarters.
- What to watch next quarter: Whether the dedicated solvent recovery plant frees up enough reactor capacity to hit the guided 35% revenue growth, whether raw material prices stabilize as expected, and whether the Chinese SDA customer actually returns in August.
SDA: The Volume-Price Disconnect
- Volume growth strong, revenue growth muted: Management expects nearly 50% volume growth in FY25, but revenue growth will cross only 25% maximum because significant raw material price reductions will flow through to lower finished-product pricing from late May or early June.
- EUR 7 as structural catalyst: When EUR 7 is implemented, it will drive 50% volume growth per vehicle, similar to what EUR 6 did in markets that had not yet adopted equivalent standards. FY26 will see an additional 30-40% volume growth from this regulation.
- China Plus One strategy executed: Raw materials for two major SDAs were always dependent on three China-based suppliers. Tatva developed in-house production to offer completely Indian-made, non-Chinese-origin material, a prerequisite to winning the business. [13-14]
- In-house raw material economics are thin: Producing these raw materials in-house saves only 10% to 15% in cost versus buying from China, but management states the business would not exist without this capability.
- New large customer ramping: Commercial supplies have begun with a couple of 100-tonne deliveries in recent months. This customer is expected to become as large as all three existing major customers combined, but the ramp will take 1.5 to 2 years.
- Existing customer volume increase: New product approvals from the existing large customer will increase volume by approximately 40-45%. Two new applications are approved with commercial orders booked; a third is expected to commence by end of Q3.
- Chinese customer remains a question mark: The Chinese SDA customer keeps promising to return after running out of inventory, with the latest promise being August, but management is not confident and plans to visit in July/August to investigate. Other business with this customer is going well.
Chintan Shah: "Though our volume growth will be 50%, I expect the maximum revenue growth to cross only 25%. So, this is the irony."
PASC: Validation Nears Completion
- All five products progressing positively: Validation of three pharma and two agro products is moving forward with no adverse comments received. Informal positive feedback has been received for all five products.
- Commercial production started for two products: Two products have already begun commercial production and inventory build-up. Commercial supplies for the two agro products are expected to begin in late Q2 or early Q3.
- Third agro product delayed by Red Sea crisis: Delivery was delayed 45-60 days due to the Suez Canal situation, pushing formal validation and commercialization from August to approximately November.
- Green chemistry as differentiator: For the six new products, Tatva offers a cleaner product by improving 1-2 stages of chemistry using continuous flow, catalytic separations, and electrolytic processes, delivering significant waste reduction. This is a sustainable chemistry play, not a price-advantage play.
- Sixth product innovation: Tatva developed in-house catalytic separation of impurities that eliminates a 20% byproduct inherent in the competitor route. The byproduct's end-use product seems likely to be banned in Europe, making the current route unsustainable. Tatva's route has no byproduct and is 100% clean, with potential to grow beyond ₹500 crore, though near-term capacity is constrained by the new plant delay.
Chintan Shah: "We have not even seen any patents being filed for what we have already done, so it is something really innovative that we come out with."
Capacity: The Bottleneck and the Fix
- Reactor utilization is lower than it appears: The reported 68% utilization includes solvent recovery and waste treatment occupying about 15% of capacity. Excluding these, effective utilization is about 50% or slightly less.
- Dedicated solvent recovery plant near completion: A separate distillation and recovery plant is almost complete and expected to be commercialized within the next couple of months. Moving solvent recovery out of the main reactors can effectively double available capacity, taking utilization from 50% to 85-90%.
- Further 5-10% capacity gain possible: Setting up dedicated waste treatment can add another 5-10% to effective utilization.
- New multi-story plant delayed: Soil testing at the planned site for a seven-floor plant at the existing Dahej location did not meet criteria. Three alternative locations within the premises are being tested. If none work, the plant will be downsized from seven floors to four floors, and reactor capacity from 150 KL to about 80-90 KL. Capex of ₹70 crore is postponed by a couple of quarters.
- Capacity constraint looms: With the guided 35% revenue growth in FY25, management expects to hit 85-90% reactor occupancy by year-end. The new plant delay means the sixth product's near-term revenue potential is limited by available capacity.
- Bromine recovery plant: Being set up and expected to be operational by August or early September.
Segment Performance and FY25 Outlook
- Phase Transfer Catalysts: FY24 revenue fell 25% YoY to ₹106.7 crore, entirely price-led. Volume was nearly stable with only a 5-7% drop, but the key raw material Tributylamine dropped from $4.2/kg to $1.6/kg, a 60-65% decline that passed through to finished product pricing while margins were maintained. FY25 revenue is expected to be stable as new business additions offset subdued agrochemical demand.
- SDAs: FY24 revenue rose 30% YoY to ₹165.5 crore on strong volume recovery. FY25 guidance is 15-20% revenue growth, with volume growth of nearly 50% offset by price reductions.
- Electrolyte Salts: FY24 revenue fell 70% YoY to ₹5 crore on poor Chinese offtake. FY25 guidance is 150-160% growth, driven by an existing customer setting up a fully automated production line for energy storage batteries (demand uptick from August 2024) and another customer qualification for hybrid car batteries with potential commercialization from end of 2024.
- PASC: FY25 guidance is 80-90% growth as commercial supplies begin for multiple products.
- Flame Retardants: Market continues at unrealistic low prices; inquiry flow is improving with better volumes but pricing has not reflected improvement. Management continues to wait for the right moment to begin commercial production.
- Polymer industry entry: Four new products developed and piloted; plant trials start next month. One key intermediate replaces hazardous high-temperature catalytic reduction with electrolytic technology. This is a very large volume opportunity but will take time as it is a new segment for Tatva.[15-16]
Chintan Shah: "If you look at that drop, it's almost 60-65% in raw material cost, and that translates into a lower price realization of the finished product. So you're maintaining your margins, but you're seeing a dramatic drop in per daily price realization."
Margins and Costs
- Gross margin maintained despite price pressure: Lower raw material costs offset price reductions, allowing gross margins to hold.
- Employee cost rose as a percentage of revenue: Employee expense increased to 13.9% of revenues from 9.7%, driven by new recruitments for the Dahej SEZ facility and R&D facility. Staff welfare expense was regrouped from other expenses to employee cost.
- Freight charges remain elevated: Persistently high through Q4; a slight reduction has appeared in the US sector recently, but European freight costs continue at elevated levels.
- Raw material prices stabilized in April: Prices of several chemicals continued declining through Q4, but stabilized in April. Management expects a turnaround within the next couple of quarters.
- FY25 EBITDA guidance: 22-24%: Management expects increasing volumes to drive EBITDA margins into the 22-24% range in FY25, up from 17.3% in FY24.
Chintan Shah: "We continue to remain confident with these increasing volumes, we should hit EBITDA in the range of 22% to 24% next year."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY25 revenue growth | 35% overall revenue growth | FY25 |
| FY25 EBITDA margin | 22% to 24% | FY25 |
| SDA volume growth | Nearly 50% volume growth, but revenue growth capped at 25% maximum | FY25 |
| Electrolyte Salts growth | 150% to 160% revenue increase | FY25 |
| PASC growth | 80% to 90% revenue increase | FY25 |
| PTC growth | 8% to 10% revenue increase | FY25 |
| SDA growth | 15% to 20% revenue increase | FY25 |
| Dedicated solvent recovery plant | Commercial operation begins, freeing reactor capacity | Within next two months |
| Bromine recovery plant | Up and running | August or early September |
| Electrolyte salts demand uptick | Significant uptick from existing customer's automated production line | Starting August 2024 |
| PASC agro commercial supplies | Two products begin commercial supplies | Late Q2 / early Q3 FY25 |
| Third agro PASC product validation | Formal validation and commercialization | Approximately November (delayed from August due to Red Sea crisis) |
| New automotive catalyst customer | REACH registration and commercial supplies begin | Within next two months |
| New large SDA customer ramp | Full-scale opportunities; customer to become as large as all three existing major customers combined | End of this year for full-scale opportunities; 1.5 to 2 years for full ramp |
| FY26 SDA volume | Additional 30-40% volume growth from EUR 7 implementation | FY26 |
| FY25 capex | ₹70 crore (postponed by a couple of quarters due to new plant soil testing delay) | FY25 |
| New plant decision | Either scale down to four floors or identify alternative site | After soil testing of three alternative locations |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Revenue from operations | ₹98.3 cr, vs ₹124.5 cr in Q4 FY23 |
| EBITDA | ₹15.6 cr, vs ₹16.3 cr in Q4 FY23 |
| EBITDA margin | 15.9%, vs 13.1% in Q4 FY23 |
| PAT | ₹9.6 cr, vs ₹17 cr in Q4 FY23 |
| PAT margin | 9.8%, vs 13.6% in Q4 FY23 |
| FY24 revenue from operations | ₹393.5 cr, 7% decline YoY |
| FY24 EBITDA | ₹68.2 cr, 13% increase YoY |
| FY24 EBITDA margin | 17.3%, vs 14.3% in FY23 |
| FY24 PAT | ₹30.4 cr, vs ₹45.5 cr in FY23 |
| FY24 employee expense | 13.9% of revenues, vs 9.7% in FY23 |
| FY24 exports | ₹276.9 cr, 70% of revenue |
| Phase Transfer Catalysts Q4 revenue | ₹27.2 cr, 10% increase QoQ, 28% decline YoY |
| SDAs Q4 revenue | ₹40.8 cr, 26% increase QoQ, 26% decline YoY |
| Pharma and Agro Intermediates Q4 revenue | ₹28 cr, 11% increase QoQ, 6% decline YoY |
| Electrolyte Salts Q4 revenue | ₹1.4 cr, 16% growth QoQ, 48% growth YoY |
| SDA volume growth guidance (FY25) | ~50%, but revenue growth expected at 15-20% due to lower price realization |
| Electrolyte Salts revenue growth guidance (FY25) | 150-160% increase |
| PASC revenue growth guidance (FY25) | 80-90% growth |
| PTC revenue growth guidance (FY25) | 8-10% growth |
| Overall revenue growth guidance (FY25) | ~35%, expected to push reactor occupancy to 85-90% by year-end |
| FY25 EBITDA margin guidance | 22-24%, driven by operating leverage as volumes increase |
| Reactor capacity utilization (FY24) | ~68%, or ~50% excluding solvent recovery and waste treatment |
| SDA assembly capacity utilization (FY24) | ~30%, crossed 55% by late April/early May |
| FY25 CAPEX | ₹70 cr, for new multi-story plant, delayed by soil testing issues |
| IPO proceeds utilization | 100% of ₹207.28 cr utilized as on 31 March 2024 |
| Average SDA realization | $8.5 to $9 per kg |
| New PASC products revenue potential | Above ₹200 cr combined, with the largest product above ₹100 cr |